Development of a scaleable process for the synthesis of the A2a agonist, UK-371,104

被引：24

作者：

Challenger, Stephen ^{[1
]}

Dessi, Yann ^{[1
]}

Fox, Darrell E. ^{[1
]}

Hesmondhalgh, Lynsey C. ^{[1
]}

Pascal, Pierre ^{[1
]}

Pettman, Alan J. ^{[1
]}

Smith, Julian D. ^{[1
]}

机构：

[1] Pfizer Global Res & Dev, Sandwich Labs, Chem Res & Dev, Sandwich CT13 9NK, Kent, England

来源：

ORGANIC PROCESS RESEARCH & DEVELOPMENT | 2008年 / 12卷 / 04期

关键词：

D O I：

10.1021/op700248t

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

The development and utilization of a scaleable process for the manufacture of the A2a agonist UK-371,104 (1) is described. Key steps in the synthesis include (i) a palladium-catalyzed cyanation reaction to prepare the nitrile 10, (ii) a telescoped conversion of the acid 11 to the glycosidation substrate 9, and (iii) the stereoselective coupling of 8 with 9 in a glycosidation reaction mediated by TMS triflate in 1,2-dimethoxyethane followed by conversion through to 1.

引用

页码：575 / 583

页数：9